📣 VC round data is live. Check it out!

Twist Bioscience Valuation Multiples

Discover Twist Bioscience's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like BillionToOne, Celcuity, 10x Genomics, Veracyte and more.

Twist Bioscience Overview

About Twist Bioscience

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company’s proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.


Founded

2013

HQ

United States

Employees

979

Financials (LTM)

Revenue: $424M
EBITDA: ($38M)

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Twist Bioscience Financials

Twist Bioscience reported last 12-month revenue of $424M and negative EBITDA of ($38M).

In the same LTM period, Twist Bioscience generated $220M in gross profit, ($38M) in EBITDA losses, and had net loss of ($111M).

Revenue (LTM)


Twist Bioscience P&L

In the most recent fiscal year, Twist Bioscience reported revenue of $377M and EBITDA of ($47M).

Twist Bioscience is unprofitable as of last fiscal year, with gross margin of 51%, EBITDA margin of (12%), and net margin of (21%).

See analyst estimates for Twist Bioscience
LTMLast FY202320242025202620272028
Revenue$424M$377M$262M$329M$394M
Gross Profit$220M$191M$101M$148M$202M
Gross Margin52%51%38%45%51%
EBITDA($38M)($47M)($175M)($160M)($92M)
EBITDA Margin(9%)(12%)(67%)(49%)(23%)
EBIT Margin(32%)(36%)(76%)(50%)(35%)
Net Profit($111M)($78M)($206M)($176M)($90M)
Net Margin(26%)(21%)(78%)(54%)(23%)

Financial data powered by Morningstar, Inc.

Twist Bioscience Stock Performance

Twist Bioscience has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


Twist Bioscience's stock price is $70.23.

Twist Bioscience share price increased by 5.0% in the last 30 days, and by 90.9% in the last year.

Twist Bioscience has an EPS (earnings per share) of $-1.25.

See more trading valuation data for Twist Bioscience
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B3.5%5.0%47.8%90.9%$-1.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Twist Bioscience Valuation Multiples

Twist Bioscience trades at 10.1x EV/Revenue multiple, and (112.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Twist Bioscience

EV / Revenue (LTM)


Twist Bioscience Financial Valuation Multiples

As of June 4, 2026, Twist Bioscience has market cap of $4B and EV of $4B.

Twist Bioscience has a P/E ratio of (39.2x).

LTMLast FY202320242025202620272028
EV/Revenue10.1x11.4x16.4x13.1x10.9x
EV/EBITDA(112.1x)(91.5x)(24.6x)(26.8x)(46.7x)
EV/EBIT(31.7x)(31.5x)(21.6x)(25.9x)(31.6x)
EV/Gross Profit19.5x22.5x42.7x29.1x21.3x
P/E(39.2x)(56.3x)(21.3x)(24.9x)(48.5x)
EV/FCF(59.4x)(63.8x)(29.6x)(60.7x)(57.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Twist Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Twist Bioscience Margins & Growth Rates

Twist Bioscience grew revenue by 19% but EBITDA decreased by 27% in the last fiscal year.

In the most recent fiscal year, Twist Bioscience reported gross margin of 51%, EBITDA margin of (12%), and net margin of (21%).

See estimated margins and future growth rates for Twist Bioscience

Twist Bioscience Margins

Last FY202420252026202720282029
Gross Margin51%45%51%53%
EBITDA Margin(12%)(49%)(23%)(5%)
EBIT Margin(36%)(50%)(35%)(27%)
Net Margin(21%)(54%)(23%)(25%)
FCF Margin(18%)(22%)(19%)(14%)

Twist Bioscience Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth19%25%20%18%
Gross Profit Growth23%47%37%22%
EBITDA Growth(27%)(8%)(43%)(74%)
EBIT Growth(1%)(17%)(18%)(8%)
Net Profit Growth65%(14%)(49%)31%
FCF Growth11%(51%)7%(12%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Twist Bioscience Operational KPIs

Twist Bioscience's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Twist Bioscience's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Twist Bioscience's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Twist Bioscience
LTMLast FY202320242025202620272028
Rule of 408%13%---
Bessemer Rule of X33%40%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue18%21%39%27%20%
Opex to Revenue-87%114%95%83%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Twist Bioscience Competitors

Twist Bioscience competitors include BillionToOne, Celcuity, 10x Genomics, Veracyte, GRAIL, Insight Lifetech, BGI Genomics, Wantai BioPharm, Genus and GeneDx.

Most Twist Bioscience public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
BillionToOne12.9x10.7x105.5x67.9x
Celcuity-193.5x(27.5x)(22.0x)
10x Genomics5.4x5.5x880.0x(74.7x)
Veracyte6.6x6.3x24.0x23.1x
GRAIL12.2x11.2x(4.8x)(5.1x)
Insight Lifetech29.2x-131.6x-
BGI Genomics3.3x3.3x42.3x38.6x
Wantai BioPharm22.7x-(320.8x)-

This data is available for Pro users. Sign up to see all Twist Bioscience competitors and their valuation data.

Start Free Trial

Twist Bioscience VC Funding History

Before going public, Twist Bioscience raised $243M in total equity funding, across 7 rounds.


Twist Bioscience Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-18Undisclosed stageE Squared Capital Management$50M--
Jun-17Undisclosed stage3W Partners; Bay City Capital; Biomatics Capital Partners; Ditch Plains Capital Management LP; Fidelity Information Services; Kangmei Pharmaceutical Co.; NFT Investment; Reinet Investments$27M-Twist Bioscience is a synthetic biology company founded in 2013 that has developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high-throughput silicon platform. The company produces synthetic biology tools, including genes, oligonucleotide pools, and variant libraries, and is headquartered in South San Francisco, California. As of fiscal year ending September 30, 2017, Twist Bioscience reported quarterly revenue of $8.50 million for the quarter ending September 30, 2017, representing 374.53% growth from the prior year quarter. The company has raised significant capital across multiple funding rounds, with investors including 3W Partners, Bay City Capital, Biomatics Capital Partners, Ditch Plains Capital Management LP, FIS, Kangmei Pharmaceutical Co., NFT Investment, and Reinet Investments S.C.A., with Biomatics Capital Partners serving as lead investor in the June 2017 round. The specific post-money valuation from the June 2017 funding round was not disclosed in publicly available financial reports or press materials indexed in standard financial databases.
Mar-17Undisclosed stageAsset Management Ventures (AMV); Dentsu Ventures$33M-Twist Bioscience is a synthetic biology company that developed a proprietary semiconductor-based process for high-throughput DNA synthesis, producing tools like genes, oligonucleotide pools, and variant libraries. Founded in 2013 and headquartered in South San Francisco, it went public via NASDAQ:TWST and focuses on life sciences applications. For traction near the 2017 round, Twist reported quarterly revenue of $10.77 million for the period ended September 30, 2017 (fiscal year 2017), up 374.53% from $2.27 million in the prior year's quarter ended September 30, 2016. Annual revenue grew rapidly post-2017, reaching $132.33 million by fiscal 2021 and $376.57 million by fiscal 2025. Twist Bioscience has expanded in the competitive synthetic biology market, with ongoing R&D investments (e.g., $80.3 million in fiscal 2025) and employee base of 979 as of recent data.
Jan-16Series D+ND Capital; ARCH Overage Fund; ARCH Venture Partners; Asset Management Ventures (AMV); Boris Nikolic; Cormorant Asset Management; Fidelity; Foresite Capital; GoldenArc Capital; Illumina Ventures; Mérieux Equity Partners; Paladin Capital Group$61M-Twist Bioscience, founded in 2013 and headquartered in South San Francisco, CA, develops a silicon-based platform for synthetic DNA manufacturing, enabling applications in personalized medicine, sustainable chemical production, agriculture, diagnostics, biodetection, and data storage. The company focuses on scaling DNA synthesis at lower costs through its proprietary technology. In January 2016, Twist Bioscience raised approximately $61 million in an oversubscribed round from crossovers including the listed investors such as +ND Capital, ARCH Overage Fund, ARCH Venture Partners, Asset Management Ventures, Boris Nikolic, Cormorant Asset Management, Fidelity, Foresite Capital, GoldenArc Capital, Illumina Ventures, Mérieux Equity Partners, and Paladin Capital Group, spotlighting potential IPO preparations. This followed a $37 million Series C in June 2015 led by Illumina with participants including Foresite Capital, Tao Invest, ARCH Venture Partners, Paladin Capital Group, and Yuri Milner, bringing total funding to $82.1 million at that point. Proceeds from the Series C were for accelerating commercial scaling post-alpha manufacturing launch and pursuing strategic opportunities like beta launch in fall 2015. By April 2016, Twist raised a small $2.6 million bridge round from 46 investors amid acquiring Genome Compiler, an Israeli gene design software startup, to integrate design and build capabilities for synthetic DNA. The beta program was progressing with initial customer shipments, planning to scale gene volume and launch an eCommerce solution by summer 2016. Later rounds included a Series D raising $120 million establishing a $1.5 billion valuation and total funding to $350 million, with another noting $400 million valuation by 2018 and IPO in 2018 raising $75 million.
Jun-15Series C+ND Capital; ARCH Venture Partners; Asset Management Ventures (AMV); Fidelity; Foresite Capital; Illumina; Joby Pritzker; Paladin Capital Group; Tao Venture Partners$37M-Twist Bioscience, founded in 2013, develops a platform for synthesizing high-quality DNA fragments and synthetic genes at low cost using silicon wafer manufacturing techniques, aiming to accelerate life science research, personalized medicine, improved agriculture, and in vivo diagnostics. The company completed an oversubscribed $37 million Series C financing round on June 9, 2015, led by Illumina, with participation from new investors Fidelity Management and Research Company, Foresite Capital Management, and existing investors including Nick and Joby Pritzker through Tao Invest, ARCH Venture Partners, Paladin Capital Group, Yuri Milner, and additional strategic corporate and venture investors. This brought total funding since inception to $82.1 million, including $10 million in debt from Silicon Valley Bank in September 2014. The proceeds were intended to accelerate a beta commercial launch in fall 2015 following an alpha manufacturing launch in April, validate product-market fit with select customers, and pursue strategic opportunities to enhance product capabilities and services. As part of the deal, Nicholas J. Naclerio from Illumina joined the board alongside existing directors including Emily Leproust (CEO), Bill Banyai (COO), Rob Chess, Paul Conley, Keith Crandell, and Fred Craves. At the time, Twist was pre-revenue, focused on commercialization of its proprietary synthetic DNA offerings.
May-14Series B+ND Capital; ARCH Venture Partners; Asset Management Ventures (AMV); Paladin Capital Group; Tao Venture Partners$26M--
Feb-14Series AARCH Venture Partners; Asset Management Ventures (AMV); Paladin Capital Group$9M--

Acquisitions by Twist Bioscience

Twist Bioscience has acquired 3 companies to date.

Last acquisition by Twist Bioscience was on November 22nd 2021. Twist Bioscience acquired Abveris for $190M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Twist Bioscience

Abveris
iGenomX
Genome Compiler
Description
Abveris is a biotechnology firm specializing in antibody discovery platforms for both reagent applications and therapeutic development. Headquartered in France with operations supporting global research, the company leverages advanced screening technologies to generate high-affinity antibodies for clients in pharmaceuticals and diagnostics. Founded to address complex target challenges, Abveris delivers custom solutions accelerating drug discovery pipelines worldwide.
iGenomX is a Boston-based genomics company developing comprehensive whole-genome sequencing for diagnosing rare genetic disorders. Its platform achieves over 99 percent coverage of known disease variants missed by exome sequencing, enabling detection of structural variants, repeat expansions, and complex rearrangements for pediatric and adult patients.
Genome Compiler is a computer-aided design platform for synthetic biology enabling collaboration and rapid biological engineering. Its tools allow biotechnology, agriculture, and pharmaceutical scientists to design, debug, and compile genetic constructs for faster bio-product development.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
Canton, OH
San Diego, CA
San Francisco, CA
Deal Date22 Nov 202130 Jun 20216 Apr 2016
Valuation$190M$35Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Twist Bioscience acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Twist Bioscience

When was Twist Bioscience founded?Twist Bioscience was founded in 2013.
Where is Twist Bioscience headquartered?Twist Bioscience is headquartered in United States.
How many employees does Twist Bioscience have?As of today, Twist Bioscience has over 979 employees.
Who is the CEO of Twist Bioscience?Twist Bioscience's CEO is Emily M. Leproust.
Is Twist Bioscience publicly listed?Yes, Twist Bioscience is a public company listed on Nasdaq.
What is the stock symbol of Twist Bioscience?Twist Bioscience trades under TWST ticker.
When did Twist Bioscience go public?Twist Bioscience went public in 2018.
Who are competitors of Twist Bioscience?Twist Bioscience main competitors include BillionToOne, Celcuity, 10x Genomics, Veracyte, GRAIL, Insight Lifetech, BGI Genomics, Wantai BioPharm, Genus, GeneDx.
What is the current market cap of Twist Bioscience?Twist Bioscience's current market cap is $4B.
What is the current revenue of Twist Bioscience?Twist Bioscience's last 12 months revenue is $424M.
What is the current revenue growth of Twist Bioscience?Twist Bioscience revenue growth (NTM/LTM) is 17%.
What is the current EV/Revenue multiple of Twist Bioscience?Current revenue multiple of Twist Bioscience is 10.1x.
Is Twist Bioscience profitable?No, Twist Bioscience is not profitable.
What is the current EBITDA of Twist Bioscience?Twist Bioscience has negative EBITDA and is not profitable.
What is Twist Bioscience's EBITDA margin?Twist Bioscience's last 12 months EBITDA margin is (9%).
What is the current EV/EBITDA multiple of Twist Bioscience?Current EBITDA multiple of Twist Bioscience is (112.1x).
What is the current FCF of Twist Bioscience?Twist Bioscience's last 12 months FCF is ($72M).
What is Twist Bioscience's FCF margin?Twist Bioscience's last 12 months FCF margin is (17%).
What is the current EV/FCF multiple of Twist Bioscience?Current FCF multiple of Twist Bioscience is (59.4x).
How many companies Twist Bioscience has acquired to date?As of June 2026, Twist Bioscience has acquired 3 companies.
What was the largest acquisition by Twist Bioscience?$190M acquisition of Abveris on 22nd November 2021 was the largest M&A Twist Bioscience has done to date.
What companies Twist Bioscience acquired?Twist Bioscience acquired Abveris, iGenomX, and Genome Compiler.
In how many companies Twist Bioscience has invested to date?Twist Bioscience hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Twist Bioscience

Lists including Twist Bioscience

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial